The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2254-2280

  Gillam, Elizabeth M J ^a   Hayes, Martin A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Biocatalysis; Cytochrome P450; Directed evolution; Drug development; High throughput screening; Metabolite identification; P450 BM3; Protein engineering

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMPHOTERICIN B; ASTEMIZOLE; AVERMECTIN; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 BM3; DOXORUBICIN; ERYTHROMYCIN; HYDROGEN PEROXIDE; NOVOBIOCIN; PRAVASTATIN; PROPRANOLOL; TOLBUTAMIDE; VANCOMYCIN; VERAPAMIL; XENOBIOTIC AGENT; ZOXAZOLAMINE;

ACTINOBACTERIA; ARTICLE; BIOCATALYST; BIOTRANSFORMATION; COMBINATORIAL CHEMISTRY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INDUSTRY; DRUG SAFETY; ENZYME SPECIFICITY; GENETIC VARIABILITY; HUMAN; ISOMERIZATION; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POLYMERASE CHAIN REACTION; PROTEIN ENGINEERING; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY; XENOBIOTIC METABOLISM;

ANIMALS; BIOCATALYSIS; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; PROTEIN ENGINEERING;

EID: 84887948410     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660158     Document Type: Article

References (250)

1. Walsh, C. Enabling the chemistry of life. Nature, 2001, 409, 226-231.
2. Knight, V.; Sanglier, J. J.; DiTullio, D.; Braccili, S.; Bonner, P.; Waters, J.; Hughes, D.; Zhang, L. Diversifying microbial natural products for drug discovery. Appl. Microbiol. Biotech, 2003, 62, 446-458.
3. Straathof, A. J. J.; Panke, S.; Schmid, A. The production of fine chemicals by biotransformations. Curr. Opin. Biotech, 2002, 13, 548-556.
4. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev, 1997, 23, 3-25.
5. Plowright, A. T.; Johnstone, C.; Kihlberg, J.; Pettersson, J.; Robb, G.; Thompson, R. A. Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle. Drug Disc. Today, 2012, 17, 56-62.
6. Food and Drug Administration, C. f. D. E. a. R. C., Guidance for Industry: Safety Testing of Drug Metabolites, United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2008.
7. Guengerich, F. P. Cytochrome P450 Enzymes in the Generation of Commercial Products. Nat. Rev. Drug Discov, 2002, 42, 359-366.
8. Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol, 2001, 14, 611-650.
9. Labinger, J. A.; Bercaw, J. E. Understanding and exploiting C-H bond activation. Nature, 2002, 417, 507-514.
10. Isin, E. M.; Guengerich, F. P. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta, 2007, 1770, 314-329.
11. Ortiz de Montellano, P. R.; Nelson, S. D. Rearrangement reactions catalyzed by cytochrome P450s. Arch. Biochem. Biophys, 2011, 507, 95-110.
12. Rittle, J.; Green, M. T. Cytochrome P450 compound I: Capture, characterization, and C-H bond activation kinetics. Science, 2010, 330, 933-937.
13. Groves, J. T.; McClusky, G. A.; White, R. E.; Coon, M. J. Aliphatic hydroxylation by highly purified liver microsomal cytochrome P-450: Evidence for a carbon radical intermediate. Biochem. Biophys. Res. Commun, 1978, 81, 154-160.
14. Groves, J. T.; Haushalter, R. C.; Nakamura, M.; Nemo, T. E.; Evans, B. J. High-valent iron-porphyrin complexes related to peroxidase and cytochrome P-450. J. Am. Chem. Soc, 1981, 103, 2884-2886.
15. Vaz, A. D. N.; McGinnity, D. F.; Coon, M. J. Epoxidation of olefins by cytochrome P450: Evidence from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant. Proc. Natl. Acad. Sci. USA, 1998, 95, 3555-3560.
16. Vaz, A. D. N.; Pernecky, S. J.; Raner, G. M.; Coon, M. J. Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: Switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4. Proc. Natl. Acad. Sci. USA, 1996, 93, 4644-4648.
17. Peterson, J. A.; Prough, R. A., in: Cytochrome P-450, Ortiz de Montellano, (Ed.) (Eds.); Plenum Press: New York, 1986, pp. 89-117.
18. Guengerich, F. P.; Johnson, W. W. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: Rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry, 1997, 36, 14741-14750.
19. Johnston, W. A.; Hunter, D. J. B.; Noble, C. J.; Hanson, G. R.; Stok, J. E.; Hayes, M. A.; De Voss, J. J.; Gillam, E. M. J. Cytochrome P450 is present in both ferrous and ferric forms in the resting state within intact Escherichia coli and hepatocytes. J. Biol. Chem, 2011, 286, 40750-40759.
20. Hrycay, E. G.; Gustafsson, J. A.; Ingelman-Sundberg, M.; Ernster, L. Sodium periodate, sodium-chlorite, organic hydroperoxides, and H2O2 as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome-P-450 Biochem. Biophys. Res. Comm, 1975, 66, 209-216.
21. Nordblom, G. D.; White, R. E.; Coon, M. J. Studies on hydroperoxide-dependent substrate hydroxylation by purified liver microsomal cytochrome-P-450. Arch. Biochem. Biophys, 1976, 175, 524-533.
22. Gorsky, L. D.; Koop, D. R.; Coon, M. J. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome-P-450-products of oxygen reduction. J. Biol. Chem, 1984, 259, 6812-6817.
23. Zangar, R. C.; Davydov, D. R.; Verma, S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol, 2004, 199, 316-331.
24. Denisov, I. G.; Grinkova, Y. V.; Baas, B. J.; Sligar, S. G. The ferrousdioxygen intermediate in human cytochrome P450 3A4-Substrate dependence of formation and decay kinetics. J. Biol. Chem, 2006, 281, 23313-23318.
25. Denisov, I. G.; Makris, T. M.; Sligar, S. G.; Schlichting, I. Structure and chemistry of cytochrome P450. Chem. Rev, 2005, 105, 2253-2277.
26. Loida, P. J.; Sligar, S. G. Molecular recognition in cytochrome P-450: mechanism for the control of uncoupling reactions. Biochemistry, 1993, 32, 11530-11538.
27. Huang, W.-C.; Westlake, A. C. G.; Maréchal, J.-D.; Joyce, M. G.; Moody, P. C. E.; Roberts, G. C. K. Filling a hole in cytochrome P450 BM3 Improves substrate binding and catalytic efficiency. J. Mol. Biol, 2007, 373, 633-651.
28. Atkins, W. M.; Sligar, S. G. Deuterium isotope effects in norcamphor metabolism by cytochrome P-450cam: kinetic evidence for the two-electron reduction of a high-valent iron-oxo intermediate. Biochemistry, 1988, 27, 1610-1616.
29. Kadkhodayan, S.; Coulter, E. D.; Maryniak, D. M.; Bryson, T. A.; Dawson, J. H. J. Biol. Chem, 1995, 270, 28042-28048.
30. French, K. J.; Rock, D. A.; Manchester, J. I.; Goldstein, B. M.; Jones, J. P. Active site mutations of cytochrome P450cam alter the binding, coupling, and oxidation of the foreign substrates (R)-and (S)-2-ethylhexanol. Arch. Biochem. Biophys, 2002, 398, 188-197.
31. Atkins, W. M.; Sligar, S. G. Metabolic switching in cytochrome P-450cam: deuterium isotope effects on regiospecificity and the monooxygenase/oxidase ratio. J. Am. Chem. Soc, 1987, 109, 3754-3760.
32. Lewis, D. F. V.; Watson, E.; Lake, B. G. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutation Res, 1998, 410, 245-270.
33. Schuler, M. A.; Werck-Reichhart, D. Functional genomics of P450s. Annu. Rev. Plant Biol, 2003, 54, 629-667.
34. Kelly, S. L.; Lamb, D. C.; Jackson, C. J.; Warrilow, A. G. S.; Kelly, D. E. The biodiversity of microbial cytochromes P450. Adv. Microb. Physiol, 2003, 47, 131-186.
35. Lepesheva, G. I.; Waterman, M. R. Structural basis for conservation in the CYP51 family. BBA-Proteins Proteomics, 2011, 1814, 88-93.
36. Cresnar, B.; Petric, S. Cytochrome P450 enzymes in the fungal kingdom. BBA-Proteins Proteomics, 2011, 1814, 29-35.
37. Nelson, D.; Werck-Reichhart, D. A P450-centric view of plant evolution. Plant J, 2011, 66, 194-211.
38. Mizutani, M.; Sato, F. Unusual P450 reactions in plant secondary metabolism. Arch. Biochem. Biophys, 2011, 507, 194-203.
39. Rendic, S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab. Rev, 2002, 34, 83-448.
40. Guengerich, F. P., in: Cytochrome P450, Ortiz de Montellano, (Ed.) (Eds.); Kluwer Academic/Plenum Publishing: New York, 2005, pp. 377-530.
41. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov, 2005, 4, 825-833.
42. Zhou, S. F.; Liu, J. P.; Lai, X. S. Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. Curr. Med. Chem, 2009, 16, 2661-2805.
43. Rettie, A. E.; Jones, J. P., in: Annu. Rev. Pharmacol. Toxicol., (Ed.) (Eds.), 2005, pp. 477-494.
44. Bu, H. Z. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: Structure-kinetics relationship assessment. Curr. Drug Metab, 2006, 7, 231-249.
45. Ekroos, M.; Sjögren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA, 2006, 103, 13682-13687.
46. Yamazaki, H.; Nakamura, M.; Komatsu, T.; Ohyama, K.; Hatanaka, N.; Asahi, S.; Shimada, N.; Guengerich, F. P.; Shimada, T.; Nakajima, M.; Yokoi, T. Roles of NADPH-P450 reductase and apo-and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Express. Purif, 2002, 24, 329-337.
47. Atkins, W. M. Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin. Drug Metab. Toxicol, 2006, 2, 573-579.
48. Lamb, D. C.; Guengerich, F. P.; Kelly, S. L.; Waterman, M. R. Exploiting Streptomyces coelicolor A3(2) P450s as a model for application in drug discovery. Expert Opin. Drug Metab. Toxicol, 2006, 2, 27-40.
49. Peterson, D. H.; Murray, H. C.; Eppstein, S. H.; Reineke, L. M.; Weintraub, A.; Meister, P. D.; Leigh, H. M. Microbiological Transformations of Steroids. I. Introduction of Oxygen at Carbon-11 of Progesterone. J. Am. Chem. Soc, 1952, 74, 5933-5936.
50. Hogg, J. A. Steroids, the steroid community, and Upjohn in perspective: a profile of innovation. Steroids, 1992, 57.
51. Urlacher, V. B.; Eiben, S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotech, 2006, 24, 324-330.
52. Petzoldt, K.; Annen, K.; Laurent, H.; Wiechert, R., Process for the preparation of 11-beta-hydroxy steroids, Schering Aktiengesellschaft, Berlin, Germany, 1982.
53. Haruyama, H.; Kuwano, H.; Kinoshita, T.; Terahara, A.; Nishigaki, T.; Tamura, C. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine. Chem. Pharm. Bull. (Tokyo), 1986, 34, 1459-1467.
54. Manzoni, M.; Rollini, M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotech, 2002, 58, 555-564.
55. Park, J. W.; Lee, J. K.; Kwon, T. J.; Yi, D. H.; Kim, Y. J.; Moon, S. H.; Suh, H. H.; Kang, S. M.; Park, Y. I. Bioconversion of compactin into pravastatin by Streptomyces sp. Biotechnol. Lett, 2003, 25, 1827-1831.
56. Ro, D. K.; Paradise, E. M.; Ouellet, M.; Fisher, K. J.; Newman, K. L.; Ndungu, J. M.; Ho, K. A.; Eachus, R. A.; Ham, T. S.; Kirby, J.; Chang, M. C. Y.; Withers, S. T.; Shiba, Y.; Sarpong, R.; Keasling, J. D. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature, 2006, 440, 940-943.
57. Lenihan, J. R.; Tsuruta, H.; Diola, D.; Renninger, N. S.; Regentin, R. Developing an Industrial Artemisinic Acid Fermentation Process to Support the Cost-Effective Production of Antimalarial Artemisinin-Based Combination Therapies. Biotechnol. Prog, 2008, 24, 1026-1032.
58. Westfall, P. J.; Pitera, D. J.; Lenihan, J. R.; Eng, D.; Woolard, F. X.; Regentin, R.; Horning, T.; Tsuruta, H.; Melis, D. J.; Owens, A.; Fickes, S.; Diola, D.; Benjamin, K. R.; Keasling, J. D.; Leavell, M. D.; McPhee, D. J.; Renninger, N. S.; Newman, J. D.; Paddon, C. J. Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. Proc. Natl. Acad. Sci. USA, 2012, 109, 6111-6118.
59. Jezequel, S. G. Microbial models of mammalian metabolism: uses and misuses (clarification of some misconceptions). J. Mol. Catal. B-Enzymatic, 1998, 5, 371-377.
60. Li, W.; Rozzell, D.; Kambourakis, S.; Mayhew, M., in: Biocatalysis for the Pharmaceutical lndustry: Discovery, Development, and Manufacturing, Tao, Lin, L, (Ed.) (Eds.); John Wiley & Sons Asia (Pte) Ltd., 2009, pp. 183-211.
61. Hall, R. M.; Dawson, M. J.; Jones, C. A.; Roberts, A. D.; Sidebottom, P. J.; Stead, P.; Taylor, N. L. The production of novel sordarin analogues by biotransformation. J. Antibiotics, 2001, 54, 948-957.
62. Webster, R.; Pacey, M.; Winchester, T.; Johnson, P.; Jezequel, S. Microbial oxidative metabolism of diclofenac: Production of 4 '-hydroxydiclofenac using Epicoccum nigrum IMI354292. Appl. Microbiol. Biotech, 1998, 49, 371-376.
63. Griffiths, D. A.; Brown, D. E.; Jezequel, S. G. Biotransformation of Warfarin by the Fungus Beauveria-Bassiana. Appl. Microbiol. Biotech, 1992, 37, 169-175.
64. Griffiths, D. A.; Brown, D. E.; Jezequel, S. G. Metabolism of Xenobiotics by Beauveria-Bassiana. Xenobiotica, 1993, 23, 1085-1100.
65. Cannell, R. J. P.; Knaggs, A. R.; Dawson, M. J.; Manchee, G. R.; Eddershaw, P. J.; Waterhouse, I.; Sutherland, D. R.; Bowers, G. D.; Sidebottom, P. J. Microbial Biotransformation of the Angiotensin-Ii Antagonist Gr117289 by Streptomyces-Rimosus to Identify a Mammalian Metabolite. Drug Metab. Dispos, 1995, 23, 724-729.
66. El Sayed, K. A. Microbial models of mammalian metabolism: microbial transformation of naproxen. Pharmazie, 2000, 55, 934-936.
67. Moody, J. D.; Freeman, J. P.; Cerniglia, C. E. Biotransformation of doxepin by Cunninghamella elegans. Drug Metab. Dispos, 1999, 27, 1157-1164.
68. Ohta, K.; Agematu, H.; Yamada, T.; Kaneko, K.; Tsuchida, T. Production of human metabolites of cyclosporin A, AM1, AM4N and AM9, by microbial conversion. J. Biosci. Bioeng, 2005, 99, 390-395.
69. Zhang, D. L.; Zhang, H. Y.; Aranibar, N.; Hanson, R.; Huang, Y.; Cheng, P. T.; Wu, S.; Bonacorsi, S.; Zhu, M. S.; Swaminathan, A.; Humphreys, W. G. Structural elucidation of human oxidative metabolites of muraglitazar: Use of microbial bioreactors in the biosynthesis of metabolite standards. Drug Metab. Dispos, 2006, 34, 267-280.
70. Zhang, D.; Hanson, R.; Roongta, V.; Dischino, D. D.; Gao, Q.; Sloan, C. P.; Polson, C.; Keavy, D.; Zheng, M.; Mitroka, J.; Yeola, S. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor. Curr. Drug Metab, 2006, 7, 883-896.
71. Zmijewski, M.; Gillespie, T. A.; Jackson, D. A.; Schmidt, D. F.; Yi, P.; Kulanthaivel, P. Application of biocatalysis to drug metabolism: Preparation of mammalian metabolites of a biaryl-bis-sulfonamide AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor potentiator using Actinoplanes missouriensis. Drug Metab. Dispos, 2006, 34, 925-931.
72. Ma, B.; Huang, H. H.; Chen, X. Y.; Sun, Y. M.; Lin, L. H.; Zhong, D. F. Biotransformation of metoprolol by the fungus Cunninghamella blakesleeana. Acta Pharmacol. Sin, 2007, 28, 1067-1074.
73. Osorio-Lozada, A.; Surapaneni, S.; Skiles, G. L.; Subramanian, R. Biosynthesis of drug metabolites using microbes in hollow fiber cartridge reactors: Case study of diclofenac metabolism by Actinoplanes species. Drug Metab. Dispos, 2008, 36, 234-240.
74. Li, W.; Josephs, J. L.; Skiles, G. L.; Humphreys, W. G. Metabolite generation via microbial biotransformations with Actinomycetes: Rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3, 5-dichlorophenyl)-1-methyl-2, 4-dioxo-1, 3, 7-triazaspiro[4. 4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and Dasatinib. Drug Metab. Dispos, 2008, 36, 721-730.
75. Tarui, N.; Ikeura, Y.; Natsugari, H.; Nakahama, K. Microbial synthesis of three metabolites of a tachykinin receptor antagonist, TAK-637. J. Biosci. Bioeng, 2001, 92, 285-287.
76. Huang, H.; Yang, X.; Li, Q.; Sun, L.; Zhong, D. Biotransformation of tolbutamide to 4'-hydroxytolbutamide by the fungus Cunninghamella blakesleeana. Appl. Microbiol. Biotech, 2006, 72, 486-491.
77. Xie, Z. Y.; Huang, H. H.; Zhong, D. F. Biotransformation of pantoprazole by the fungus Cunninghamella blakesleeana. Xenobiotica, 2005, 35, 467-477.
78. Sutherland, J. B.; Freeman, J. P.; Heinze, T. M.; Moody, J. D.; Parshikov, I. A.; Williams, A. J.; Zhang, D. Oxidation of phenothiazine and phenoxazine by Cunninghamella elegans. Xenobiotica, 2001, 31, 799-809.
79. Moody, J. D.; Freeman, J. P.; Fu, P. P.; Cerniglia, C. E. Biotransformation of mirtazapine by Cunninghamella elegans. Drug Metab. Dispos, 2002, 30, 1274-1279.
80. Sun, L.; Huang, H. H.; Liu, L.; Zhong, D. F. Transformation of verapamil by Cunninghamella blakesleeana. Appl. Environ. Microbiol, 2004, 70, 2722-2727.
81. Li, L.; Liu, R.; Ye, M.; Hu, X.; Wang, Q.; Bi, K.; Guo, D. Microbial metabolism of evodiamine by Penicillium janthinellum and its application for metabolite identification in rat urine. Enzyme Microb. Technol, 2006, 39, 561-567.
82. Cannell, R. J. P.; Rashid, T.; Ismail, I. M.; Sidebottom, P. J.; Knaggs, A. R.; Marshall, P. S. Novel metabolites of warfarin produced by Beauveria bassiana and Streptomyces rimosus: A novel application of hplc-nmr. Xenobiotica, 1997, 27, 147-157.
83. Freitag, D. G.; Foster, R. T.; Coutts, R. T.; Pickard, M. A.; Pasutto, F. M. Stereoselective metabolism of rac-Mexiletine by the fungus Cunninghamella echinulata yields the major human metabolites hydroxymethylmexiletine and p-hydroxymexiletine. Drug Metab. Dispos, 1997, 25, 685-692.
84. Moussa, C.; Houziaux, P.; Danree, B.; Azerad, R. Microbial models of mammalian metabolism-Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. 2. Metabolites of nonphenolic derivatives. Drug Metab. Dispos, 1997, 25, 311-316.
85. Moussa, C.; Houziaux, P.; Danree, B.; Azerad, R. Microbial models of mammalian metabolism-Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. 1. Metabolites of thymoxamine. Drug Metab. Dispos, 1997, 25, 301-310.
86. Lacroix, I.; Biton, J.; Azerad, R. Microbial biotransformations of a synthetic immunomodulating agent, HR325. Bioorg. Medicinal Chem, 1997, 5, 1369-1380.
87. Dragan, C.-A.; Peters, F. T.; Bour, P.; Schwaninger, A. E.; Schaan, S. M.; Neunzig, I.; Widjaja, M.; Zapp, J.; Kraemer, T.; Maurer, H. H.; Bureik, M. Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems. Appl. Biochem. Biotechnol, 2011, 163, 965-980.
88. Vail, R. B.; Homann, M. J.; Hanna, I.; Zaks, A. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J. Indust. Microbiol. Biotech, 2005, 32, 67-74.
89. Rushmore, T. H.; Reider, P. J.; Slaughter, D.; Assang, C.; Shou, M. Bioreactor systems in drug metabolism: Synthesis of cytochrome P450-generated metabolites. Metab. Eng, 2000, 2, 115-125.
90. Nicoll-Griffith, D. A.; Seto, C.; Aubin, Y.; Levesque, J. F.; Chauret, N.; Day, S.; Silva, J. M.; Trimble, L. A.; Truchon, J. F.; Berthelette, C.; Lachance, N.; Wang, Z. Y.; Sturino, C.; Braun, M.; Zamboni, R.; Young, R. N. In vitro biotransformations of the prostaglandin D-2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg. Medicinal Chem. Lett, 2007, 17, 301-304.
91. Schroer, K.; Kittelmann, M.; Lutz, S. Recombinant Human Cytochrome P450 Monooxygenases for Drug Metabolite Synthesis. Biotechnol. Bioeng, 2010, 106, 699-706.
92. Burton, S. G.; Cowan, D. A.; Woodley, J. M. The search for the ideal biocatalyst. Nat. Biotech, 2002, 20, 37-45.
93. Noble, M. A.; Miles, C. S.; Chapman, S. K.; Lysek, D. A.; Mackay, A. C.; Reid, G. A.; Hanzlik, R. P.; Munro, A. W. Roles of key activesite residues in flavocytochrome P450 BM3. Biochem. J, 1999, 339, 371-379.
94. Amann, R. I.; Ludwig, W.; Schleifer, K. Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol. Rev, 1995, 59, 143-169.
95. Kim, B. S.; Kim, S. Y.; Park, J.; Park, W.; Hwang, K. Y.; Yoon, Y. J.; Oh, W. K.; Kim, B. Y.; Ahn, J. S. Sequence-based screening for selfsufficient P450 monooxygenase from a metagenome library. J. Appl. Microbiol, 2007, 102, 1392-1400.
96. Jung, C., in: The Ubiquitous Roles of Cytochrome P450 Proteins, Sigel, Sigel, Sigel, (Ed.) (Eds.); John Wiley & Sons, Ltd: Hoboken, NJ, 2007, pp. 187-234.
97. Schacter, B. A.; Nelson, E. B.; Marver, H. S.; Masters, B. S. J. Biol. Chem, 1972, 247, 3601-3607.
98. Enoch, H. G.; Strittmatter, P. J. Biol. Chem, 1979, 254, 8976-8981.
99. Ilan, Z.; Ilan, R.; Cinti, D. L. Evidence for a new physiological role of hepatic NADPH: ferricytochrome (P-450) oxidoreductase: direct electron input to the microsomal fatty acid chain elongation system. J. Biol. Chem, 1981, 256, 10066-10072.
100. Ono, T.; Ozasa, S.; Hasegawa, F.; Imai, Y. Involvement of NADPH-cytochrome c-reductase in rat liver squalene epoxidase system. Biochim. Biophys. Acta, 1977, 486, 401-407.
101. Nishino, H.; Ishibashi, T. Evidence for requirement of NADPHcytochrome P450 oxidoreductase in the microsomal NADPH-sterol D7-reductase system,. Arch. Biochem. Biophys, 2000, 374, 293-298.
102. Shimada, T.; Mernaugh, R. L.; Guengerich, F. P. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes. Arch. Biochem. Biophys, 2005, 435, 207-216.
103. Tan, Y.; Patten, C. J.; Smith, T.; Yang, C. S. Competitive interactions between cytochromes P450 2A6 and 2E1 for NADPHcytochrome P450 oxidoreductase in the microsomal membranes produced by a baculovirus expression system. Arch. Biochem. Biophys, 1997, 342, 82-91.
104. Li, D. N.; Pritchard, M. P.; Hanlon, S. P.; Burchell, B.; Wolf, C. R.; Friedberg, T. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. J. Pharmacol. Exp. Ther, 1999, 289, 661-667.
105. Chauret, N.; Gauthier, A.; Nicoll-Griffith, D. A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos, 1998, 26, 1-4.
106. Hickman, D.; Wang, J. P.; Wang, Y.; Unadkat, J. D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos, 1998, 26, 207-215.
107. Easterbrook, J.; Lu, C.; Sakai, Y.; Li, A. P. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDPdependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab. Dispos, 2001, 29, 141-144.
108. Busby, W. F.; Ackermann, J. M.; Crespi, C. L. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos, 1999, 27, 246-249.
109. Wong, T. S.; Arnold, F. H.; Schwaneberg, U. Laboratory evolution of cytochrome P450 BM-3 monooxygenase for organic cosolvents. Biotechnol. Bioeng, 2004, 85, 351-358.
110. Guengerich, F. P., in: Principles and Methods of Toxicology, Hayes, (Ed.) (Eds.); Raven Press, Ltd.: New York, 1994, pp. 1259-1313.
111. Guengerich, F. P.; Martin, M. V.; Guo, Z.; Chun, Y.-J. Purification of recombinant human cytochrome P450 enzymes expressed in bacteria. Methods Enzymol, 1996, 272, 35-44.
112. Hunter, D. J. B.; Behrendorff, J. B. Y. H.; Johnston, W. A.; Huang, W.; Bonn, B.; Hayes, M. A.; De Voss, J. J.; Gillam, E. M. J. Facile production of minor metabolites for drug development using a CYP3A shuffled library. Metab. Eng, 2011, 13, 682-693.
113. Wong, T. S.; Zhurina, D.; Schwaneberg, U. The diversity challenge in directed protein evolution. Combinat. Chem. High Throughput Screen, 2006, 9, 271-288.
114. Kaur, J.; Sharma, R. Directed evolution: An approach to engineer enzymes. Crit. Rev. Biotechnol, 2006, 26, 165-199.
115. Shivange, A. V.; Marienhagen, J.; Mundhada, H.; Schenk, A.; Schwaneberg, U. Advances in generating functional diversity for directed protein evolution. Curr. Opin. Chem. Biol, 2009, 13, 19-25.
116. Lutz, S. Beyond directed evolution-Semi-rational protein engineering and design. Curr. Opin. Biotech, 2010, 21, 734-743.
117. Drummond, D. A.; Silberg, J. J.; Meyer, M. M.; Wilke, C. O.; Arnold, F. H. On the conservative nature of intragenic recombination. Proc. Natl. Acad. Sci. USA, 2005, 102, 5380-5385.
118. Huang, W.; Johnston, W. A.; Hayes, M. A.; De Voss, J. J.; Gillam, E. M. J. A shuffled CYP2C library with a high degree of structural integrity and functional versatility. Arch. Biochem. Biophys, 2007, 467, 193-205.
119. Johnston, W. A.; Huang, W.; De Voss, J. J.; Hayes, M. A.; Gillam, E. M. J. A shuffled CYP1A library shows both structural integrity and functional diversity. Drug Metab. Dispos, 2007, 35, 2177-2185.
120. Voigt, C. A.; Martinez, C.; Wang, Z. G.; Mayo, S. L.; Arnold, F. H. Protein building blocks preserved by recombination. Nat. Struct. Biol, 2002, 9, 553-558.
121. Bershtein, S.; Tawfik, D. S. Advances in laboratory evolution of enzymes. Curr. Opin. Chem. Biol, 2007, 12, 1-8.
122. Whitehouse, C. J. C.; Bell, S. G.; Wong, L. L. P450(BM3) (CYP102A1): connecting the dots. Chem. Soc. Rev, 2012, 41, 1218-1260.
123. Lewis, J. C.; Mantovani, S. M.; Fu, Y.; Snow, C. D.; Komor, R. S.; Wong, C. H.; Arnold, F. H. Combinatorial alanine substitution enables rapid optimization of cytochrome P450(BM3) for selective hydroxylation of large substrates. Chembiochem, 2010, 11, 2502-2505.
124. Sieber, V.; Martinez, C. A.; Arnold, F. H. Libraries of hybrid proteins from distantly related sequences. Nat. Biotech, 2001, 19, 456-460.
125. Bloom, J. D.; Labthavikul, S. T.; Otey, C. R.; Arnold, F. H. Protein stability promotes evolvability. Proc. Natl. Acad. Sci. USA, 2006, 103, 5869-5874.
126. Otey, C. R.; Landwehr, M.; Endelman, J. B.; Hiraga, K.; Bloom, J. D.; Arnold, F. H. Structure-guided recombination creates an artificial family of cytochromes P450. PLoS. Biol, 2006, 4, e112.
127. Bloom, J. D.; Romero, P. A.; Lu, Z. Y.; Arnold, F. H. Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution. Biol. Direct, 2007, 2.
128. Landwehr, M.; Carbone, M.; Otey, C. R.; Li, Y.; Arnold, F. H. Diversification of catalytic function in a synthetic family of chimeric cytochrome P450s. Chem. Biol, 2007, 14, 237-238.
129. Li, Y. G.; Drummond, D. A.; Sawayama, A. M.; Snow, C. D.; Bloom, J. D.; Arnold, F. H. A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments. Nat. Biotech, 2007, 25, 1051-1056.
130. Joo, H.; Lin, Z.; Arnold, F. H. Laboratory evolution of peroxidemediated cytochrome P450 hydroxylation. Nature, 1999, 399, 670-673.
131. Cryle, M. J.; Espinoza, R. D.; Smith, S. J.; Matovic, N. J.; De Voss, J. J. Are branched chain fatty acids the natural substrates for P450(BM3)? Chem. Commun, 2006, 2353-2355.
132. Ravichandran, K. G.; Boddupalli, S. S.; Hasemann, C. A.; Peterson, J. A.; Deisenhofer, J. Crystal-Structure of Hemoprotein Domain of P450bm-3, a Prototype for Microsomal P450s. Science, 1993, 261, 731-736.
133. Li, H. Y.; Poulos, T. L. The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat. Struct. Biol, 1997, 4, 140-146.
134. Haines, D. C.; Tomchick, D. R.; Machius, M.; Peterson, J. A. Pivotal Role of Water in the Mechanism of P450BM-3. Biochemistry, 2001, 40, 13456-13465.
135. Haines, D. C.; Chen, B.; Tomchick, D. R.; Bondlela, M.; Hegde, A.; Machius, M.; Peterson, J. A. Crystal structure of inhibitor-bound P450BM-3 reveals open conformation of substrate access channel. Biochemistry, 2008, 47, 3662-3670.
136. Graham-Lorence, S.; Truan, G.; Peterson, J. A.; Falck, J. R.; Wei, S. Z.; Helvig, C.; Capdevila, J. H. An active site substitution, F87V, converts cytochrome p450 BM-3 into a regio-and stereoselective (14S, 15R)-arachidonic acid epoxygenase. J. Biol. Chem, 1997, 272, 1127-1135.
137. Li, Q. S.; Ogawa, J.; Schmid, R. D.; Shimizu, S. Residue size at position 87 of cytochrome P450BM-3 determines its stereoselectivity in propylbenzene and 3-chlorostyrene oxidation. FEBS Lett, 2001, 508, 249-252.
138. Cirino, P. C.; Arnold, F. H. Regioselectivity and activity of cytochrome P450 BM-3 and mutant F87A in reactions driven by hydrogen peroxide. Adv. Synth. Catal, 2002, 344, 932-937.
139. Schwaneberg, U.; Schmidt-Dannert, C.; Schmitt, J.; Schmid, R. D. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Anal. Biochem, 1999, 269, 359-366.
140. Sulistyaningdyah, W. T.; Ogawa, J.; Li, Q. S.; Maeda, C.; Yano, Y.; Schmid, R. D.; Shimizu, S. Hydroxylation activity of P450BM-3 mutant F87V towards aromatic compounds and its application to the synthesis of hydroquinone derivatives from phenolic compounds. Appl. Microbiol. Biotech, 2005, 67, 556-562.
141. Oliver, C. F.; Modi, S.; Primrose, W. U.; Lian, L. Y.; Roberts, G. C. K. Engineering the substrate specificity of Bacillus megaterium cytochrome P-450 BM3: hydroxylation of alkyl trimethylammonium compounds. Biochem. J, 1997, 327, 537-544.
142. Carmichael, A. B.; Wong, L.-L. Protein engineering of Bacillus megaterium CYP102: The oxidation of polycyclic aromatic hydrocarbons. Eur. J. Biochem, 2001, 268, 3117-3125.
143. Sowden, R. J.; Yasmin, S.; Rees, N. H.; Bell, S. G.; Wong, L. L. Biotransformation of the sesquiterpene (+)-valencene by cytochrome P450cam and P450BM-3. Org Biomol. Chem, 2005, 3, 57-64.
144. Wong, T. S.; Wu, N.; Roccatano, D.; Zacharias, M.; Schwaneberg, U. Sensitive assay for laboratory evolution of hydroxylases toward aromatic and heterocyclic compounds. J. Biomol. Screen, 2005, 10, 246-252.
145. Li, Q. S.; Schwaneberg, U.; Fischer, M.; Schmitt, J.; Pleiss, J.; Lutz-Wahl, S.; Schmid, R. D. Rational evolution of a medium chainspecific cytochrome P-450 BM-3 variant. Biochim. Biophys. Acta, 2001, 1545, 114-121.
146. Lentz, O.; Qing-Shang, L. I.; Schwaneberg, U.; Lutz-Wahl, S.; Fischer, P.; Schmid, R. D. Modification of the fatty acid specificity of cytochrome P450BM-3 from Bacillus megaterium by directed evolution: A validated assay. J. Mol. Catal. B-Enzymatic, 2001, 15, 123-133.
147. Seifert, A.; Vomund, S.; Grohmann, K.; Kriening, S.; Urlacher, V. B.; Laschat, S.; Pleiss, J. Rational Design of a Minimal and Highly Enriched CYP102A1 Mutant Library with Improved Regio-, Stereo-and Chemoselectivity. Chembiochem, 2009, 10, 853-861.
148. Farinas, E. T.; Schwaneberg, U.; Glieder, A.; Arnold, F. H. Directed evolution of a cytochrome P450 monooxygenase for alkane oxidation. Adv. Synth. Catal, 2001, 343, 601-606.
149. Urlacher, V. B.; Makhsumkhanov, A.; Schmid, R. D. Biotransformation of beta-ionone by engineered cytochrome P450BM-3. Appl. Microbiol. Biotech, 2006, 70, 53-59.
150. Li, H. M.; Mei, L. H.; Urlacher, V. B.; Schmid, R. D. Cytochrome P450BM-3 evolved by random and saturation mutagenesis as an effective indole-hydroxylating catalyst. Appl. Biochem. Biotechnol, 2008, 144, 27-36.
151. Di Nardo, G.; Fantuzzi, A.; Sideri, A.; Panicco, P.; Sassone, C.; Giunta, C.; Gilardi, G. Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J. Biol. Inorg. Chem, 2007, 12, 313-323.
152. Lussenburg, B. M. A.; Babel, L. C.; Vermeulen, N. P. E.; Commandeur, J. N. M. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450BM3 and site-directed mutants. Anal. Biochem, 2005, 341, 148-155.
153. van Vugt-Lussenburg, B. M. A.; Damsten, M. C.; Maasdijk, D. M.; Vermeulen, N. P. E.; Commandeur, J. N. M. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem. Biophys. Res. Comm, 2006, 346, 810-818.
154. van Vugt-Lussenburg, B. M. A.; Stjernschantz, E.; Lastdrager, J.; Oostenbrink, C.; Vermeulen, N. P. E.; Commandeur, J. N. M. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J. Med. Chem, 2007, 50, 455-461.
155. Otey, C. R.; Bandara, G.; Lalonde, J.; Takahashi, K.; Arnold, F. H. Preparation of human metabolites of propranolol using laboratoryevolved bacterial cytochromes P450. Biotechnol. Bioeng, 2006, 93, 494-499.
156. Damsten, M. C.; van Vugt-Lussenburg, B. M. A.; Zeldenthuis, T.; de Vlieger, J. S. B.; Commandeur, J. N. M.; Vermeulen, N. P. E. Application of drug metabolising mutants of cytochrome P450BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem.-Biol. Interact, 2008, 171, 96-107.
157. Boerma, J. S.; Vermeulen, N. P. E.; Commandeur, J. N. M. Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites. Chem. Res. Toxicol, 2011, 24, 1263-1274.
158. Vottero, E.; Rea, V.; Lastdrager, J.; Honing, M.; Vermeulen, N. P. E.; Commandeur, J. N. M. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11. J. Biol. Inorg. Chem, 2011, 16, 899-912.
159. Reinen, J.; van Leeuwen, J. S.; Li, Y. M.; Sun, L. F.; Grootenhuis, P. D. J.; Decker, C. J.; Saunders, J.; Vermeulen, N. P. E.; Commandeur, J. N. M. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of druglike molecules in chemical space. Drug Metab. Dispos, 2011, 39, 1568-1576.
160. Dietrich, M.; Do, T. A.; Schmid, R. D.; Pleiss, J.; Urlacher, V. B. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma-and delta-positions. J. Biotechnol, 2009, 139, 115-117.
161. Li, Q. S.; Schwaneberg, U.; Fischer, P.; Schmid, R. D. Directed evolution of the fatty-acid hydyoxylase P450BM-3 into an indolehydroxylating catalyst. Chem.-Eur. J, 2000, 6, 1531-1536.
162. Fasan, R.; Chen, M. M.; Crook, N. C.; Arnold, F. H. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties. Angew. Chem. Int. Ed, 2007, 46, 8414-8418.
163. Reinen, J.; Kool, J.; Vermeulen, N. P. E. Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization. Analytical and Bioanalytical Chemistry, 2008, 390, 1987-1998.
164. Reinen, J.; Ferman, S.; Vottero, E.; Vermeulen, N. P. E.; Commandeur, J. N. M. Application of a Fluorescence-Based Continuous-Flow Bioassay to Screen for Diversity of Cytochrome P450 BM3 Mutant Libraries. J. Biomol. Screen, 2011, 16, 239-250.
165. Reinen, J.; Kalma, L. L.; Begheijn, S.; Heus, F.; Commandeur, J. N. M.; Vermeulen, N. P. E. Application of cytochrome P450 BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone. Xenobiotica, 2011, 41, 59-70.
166. Li, Q. S.; Ogawa, J.; Schmid, R. D.; Shimizu, S. Engineering cytochrome P450BM-3 for oxidation of polycyclic aromatic hydrocarbons. Appl. Environ. Microbiol, 2001, 67, 5735-5739.
167. Kim, D. H.; Kim, K. H.; Kim, D. H.; Liu, K. H.; Jung, H. C.; Pan, J. G.; Yun, C. H. Generation of Human Metabolites of 7-Ethoxycoumarin by Bacterial Cytochrome P450BM3. Drug Metab. Dispos, 2008, 36, 2166-2170.
168. Kim, D. H.; Ahn, T.; Jung, H. C.; Pan, J. G.; Yun, C. H. Generation of the Human Metabolite Piceatannol from the Anticancer-Preventive Agent Resveratrol by Bacterial Cytochrome P450 BM3. Drug Metab. Dispos, 2009, 37, 932-936.
169. Kim, D. H.; Kim, K. H.; Kim, D.; Jung, H. C.; Pan, J. G.; Chi, Y. T.; Ahn, T.; Yun, C. H. Oxidation of human cytochrome P450 1A2 substrates by Bacillus megaterium cytochrome P450 BM3. J. Mol. Catal. B-Enzymatic, 2010, 63, 179-187.
170. Kim, K. H.; Kang, J. Y.; Kim, D. H.; Park, S. H.; Park, S. H.; Kim, D.; Park, K. D.; Lee, Y. J.; Jung, H. C.; Pan, J. G.; Ahn, T.; Yun, C. H. Generation of Human Chiral Metabolites of Simvastatin and Lovastatin by Bacterial CYP102A1 Mutants. Drug Metab. Dispos, 2011, 39, 140-150.
171. Park, S. H.; Kim, D. H.; Kim, D.; Kim, D. H.; Jung, H. C.; Pan, J. G.; Ahn, T.; Kim, D.; Yun, C. H. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation. Drug Metab. Dispos, 2010, 38, 732-739.
172. Gillam, E. M. J.; Notley, L. M.; Cai, H. L.; De Voss, J. J.; Guengerich, F. P. Oxidation of indole by cytochrome P450 enzymes. Biochemistry, 2000, 39, 13817-13824.
173. Whitehouse, C. J. C.; Bell, S. G.; Tufton, H. G.; Kenny, R. J. P.; Ogilvie, L. C. I.; Wong, L. L. Evolved CYP102A1 (P450(BM3) variants oxidise a range of non-natural substrates and offer new selectivity options. Chem. Commun, 2008, 966-968.
174. Fasan, R.; Meharenna, Y. T.; Snow, C. D.; Poulos, T. L.; Arnold, F. H. Evolutionary History of a Specialized P450 Propane Monooxygenase. J. Mol. Biol, 2008, 383, 1069-1080.
175. Tsotsou, G. E.; Sideri, A.; Goyal, A.; Di Nardo, G.; Gilardi, G. Identification of mutant Asp251Gly/Gln307His of cytochrome P450 BM3 for the generation of metabolites of diclofenac, ibuprofen and tolbutamide. Chem.-Eur. J, 2012, 18, 3582-3588.
176. Landwehr, M.; Hochrein, L.; Otey, C. R.; Kasrayan, A.; Bäckvall, J.-E.; Arnold, F. H. Enantioselective J-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J. Am. Chem. Soc, 2006, 128, 6058-6059.
177. Peters, M. W.; Meinhold, P.; Glieder, A.; Arnold, F. H. Regio-and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J. Am. Chem. Soc, 2003, 125, 13442-13450.
178. Meinhold, P.; Peters, M. W.; Hartwick, A.; Hernandez, A. R.; Arnold, F. H. Engineering cytochrome P450BM3 for terminal alkane hydroxylation. Adv. Synth. Catal, 2006, 348, 763-772.
179. Cirino, P. C.; Arnold, F. H. A self-sufficient peroxide-driven hydroxylation biocatalyst. Angew. Chem. Int. Ed. Engl, 2003, 42, 3299-3301.
180. Rentmeister, A.; Brown, T. R.; Snow, C. D.; Carbone, M. N.; Arnold, F. H. Engineered bacterial mimics of human drug metabolizing enzyme CYP2C9. ChemCatChem, 2011, 3, 1065-1071.
181. Weis, R.; Winkler, M.; Schittmayer, M.; Kambourakis, S.; Vink, M.; Rozzell, J. D.; Glieder, A. A diversified library of bacterial and fungal bifunctional cytochrome P450 enzymes for drug metabolite synthesis. Adv. Synth. Catal, 2009, 351, 2140-2146.
182. Jung, S. T.; Lauchli, R.; Arnold, F. H. Cytochrome P450: taming a wild type enzyme. Curr. Opin. Biotech, 2011, 22, 809-817.
183. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell, 2000, 5, 121-131.
184. Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dansette, P. M.; Mansuy, D.; Stout, C. D. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2. 3 angstrom resolution: Evidence for multiple substrate binding modes. Biochemistry, 2003, 42, 6370-6379.
185. Schoch, G. A.; Yano, J. K.; Wester, M. R.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem, 2004, 279, 9497-9503.
186. Scott, E. E.; He, Y. A.; Wester, M. R.; White, M. A.; Chin, C. C.; Halpert, J. R.; Johnson, E. F.; Stout, C. D. An open conformation of mammalian cytochrome P450 2B4 at 1. 6-Å resolution. Proc. Natl. Acad. Sci. USA, 2003, 100, 13121-13126.
187. Scott, E. E.; White, M. A.; He, Y. A.; Johnson, E. F.; Stout, C. D.; Halpert, J. R. Structure of mammalian cytochrome P4502B4 complexed with 4-(4-chlorophenyl) imidazole at 1. 9-angstrom resolution-Insight into the range of P450 conformations and the coordination of redox partner binding. J. Biol. Chem, 2004, 279, 27294-27301.
188. Schoch, G. A.; Yano, J. K.; Sansen, S.; Dansette, P. M.; Stout, C. D.; Johnson, E. F. Determinants of cytochrome P4502C8 substrate binding-Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J. Biol. Chem, 2008, 283, 17227-17237.
189. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Adaptations of the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem, 2007, 282, 14348-14355.
190. Yano, J. K.; Hsu, M. H.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol, 2005, 12, 822-823.
191. Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2. 05-A resolution. J. Biol. Chem, 2004, 279, 38091-38094.
192. Smith, B. D.; Sanders, J. L.; Porubsky, P. R.; Lushington, G. H.; Stout, C. D.; Scott, E. E. Structure of the human lung cytochrome P450 2A13. J. Biol. Chem, 2007, 282, 17306-17313.
193. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Vinkovic, D. M.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424, 464-468.
194. Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove, H. C.; Day, P. J.; Vonrhein, C.; Tickle, I. J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305, 683-686.
195. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem, 2006, 281, 7614-7622.
196. Porubsky PR, M. K., Scott EE. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem, 2008, 283, 283(248): 33698-33707.
197. Porubsky, P. R.; Battaile, K. P.; Scott, E. E. Human Cytochrome P450 2E1 Structures with Fatty Acid Analogs Reveal a Previously Unobserved Binding Mode. J. Biol. Chem, 2010, 285, 22282-22290.
198. Wang, A.; Savas, U.; Stout, C. D.; Johnson, E. F. Structural Characterization of the Complex between alpha-Naphthoflavone and Human Cytochrome P450 1B1. J. Biol. Chem, 2011, 286, 5736-5743.
199. Kumar, S.; Scott, E. E.; Liu, H.; Halpert, J. R. A rational approach to re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5. J. Biol. Chem, 2003, 278, 17178-17184.
200. Chen, C.-S.; Lin, J. T.; Goss, K. A.; He, Y.-A.; Halpert, J. R.; Waxman, D. J. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol, 2004, 65, 1278-1285.
201. Nguyen, T.-A.; Tychopoulos, M.; Bichat, F.; Zimmermann, C.; Flinois, J.-P.; Diry, M.; Ahlberg, E.; Delaforge, M.; Corcos, L.; Beaune, P.; Dansette, P.; Andre, F.; de Waziers, I. Improvement of cyclophosphamide activation by CYP2B6 mutants: From in silico to ex vivo. Mol. Pharmacol, 2008, 73, 1122-1133.
202. Sun, L.; Chen, C. S.; Waxman, D. J.; Liu, H.; Halpert, J. R.; Kumar, S. Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Arch. Biochem. Biophys, 2007, 458, 167-174.
203. Kumar, S.; Chen, C. S.; Waxman, D. J.; Halpert, J. R. Directed evolution of mammalian cytochrome P450 2B1. Mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J. Biol. Chem, 2005, 280, 19569-19575.
204. Parikh, A.; Josephy, P. D.; Guengerich, F. P. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry, 1999, 38, 5283-5289.
205. Kim, D.; Guengerich, F. P. Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation. Biochemistry, 2004, 43, 981-988.
206. Kim, D.; Guengerich, F. P. Enhancement of 7-methoxyresorufin Odemethylation activity of human cytochrome P450 1A2 by molecular breeding. Arch. Biochem. Biophys, 2004, 432, 102-108.
207. Abécassis, V.; Urban, P.; Aggerbeck, L.; Truan, G.; Pompon, D. Exploration of natural and artificial sequence spaces: Towards a functional remodeling of membrane-bound cytochrome P450. Biocat. Biotrans, 2003, 21, 55-66.
208. Gillam, E. M. J.; Aguinaldo, A. M. A.; Notley, L. M.; Kim, D.; Mundkowski, R. G.; Volkov, A. A.; Arnold, F. H.; Soucek, P.; De-Voss, J. J.; Guengerich, F. P. Formation of indigo by recombinant mammalian cytochrome P450. Biochem. Biophys. Res. Comm, 1999, 265, 469-472.
209. Nakamura, K.; Martin, M. V.; Guengerich, F. P. Random mutagenesis of human cytochrome P450 2A6 and screening with indole oxidation products. Arch. Biochem. Biophys, 2001, 395, 25-31.
210. Guengerich, F. P.; Sorrells, J. L.; Schmitt, S.; Krauser, J. A.; Aryal, P.; Meijer, L. Generation of new protein kinase inhibitors utilizing cytochrome P450 mutant enzymes for indigoid synthesis. J. Med. Chem, 2004, 47, 3236-3241.
211. Wu, Z. L. L.; Aryal, P.; Lozach, O.; Meijer, L.; Guengerich, E. P. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Chem. Biodivers, 2005, 2, 51-65.
212. Wu, Z. L.; Podust, L. M.; Guengerich, F. P. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J. Biol. Chem, 2005, 280, 41090-41100.
213. Kim, D.; Wu, Z. L.; Guengerich, F. P. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J. Biol. Chem, 2005, 280, 40319-40327.
214. Kumar, S.; Liu, H.; Halpert, J. R. Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab. Dispos, 2006, 34, 1958-1965.
215. Kumar, S.; Sun, L.; Liu, H.; Muralidhara, B. K.; Halpert, J. R. Engineering mammalian cytochrome P450 2B1 by directed evolution for enhanced catalytic tolerance to temperature and dimethyl sulfoxide. Protein Eng. Des. Sel, 2006, 19, 547-554.
216. Crameri, A.; Raillard, S. A.; Bermudez, E.; Stemmer, W. P. C. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature, 1998, 391, 288-291.
217. Abécassis, V.; Pompon, D.; Truan, G. High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast: statistical and functional analysis of a combinatorial library between human cytochrome P450 1A1 and 1A2. Nucl. Acids Res, 2000, 28, e88.
218. Taly, V.; Urban, P.; Truan, G.; Pompon, D. A combinatorial approach to substrate discrimination in the P450 CYP1A subfamily. Biochim. Biophys. Acta, 2007, 1770, 446-457.
219. Rosic, N. N.; Huang, W.; Johnston, W. A.; DeVoss, J. J.; Gillam, E. M. J. Extending the diversity of cytochrome P450 enzymes by DNA family shuffling. Gene, 2007, 395, 40-48.
220. Endelman, J. B.; Silberg, J. J.; Wang, Z. G.; Arnold, F. H. Sitedirected protein recombination as a shortest-path problem. Protein Eng. Des. Sel, 2004, 17, 589-594.
221. Hiraga, K.; Arnold, F. H. General method for sequence-independent site-directed chimeragenesis. J. Mol. Biol, 2003, 330, 287-296.
222. Li, Y. G.; Drummond, D. A.; Sawayama, A. M.; Snow, C. D.; Bloom, J. D.; Arnold, F. H. A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments (vol 25, pg 1051, 2007). Nat. Biotech, 2007, 25, 1488-1488.
223. Sawayama, A. M.; Chen, M. M. Y.; Kulanthaivel, P.; Kuo, M. S.; Hemmerle, H.; Arnold, F. H. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chem.-Eur. J, 2009, 15, 11723-11729.
224. Rentmeister, A.; Arnold, F. H.; Fasan, R. Chemo-enzymatic fluorination of unactivated organic compounds. Nat. Chem. Biol, 2009, 5, 26-28.
225. Lewis, J. C.; Bastian, S.; Bennett, C. S.; Fu, Y.; Mitsuda, Y.; Chen, M. M.; Greenberg, W. A.; Wong, C. H.; Arnold, F. H. Chemoenzymatic elaboration of monosaccharides using engineered cytochrome P450(BM3) demethylases. Proc. Natl. Acad. Sci. USA, 2009, 106, 16550-16555.
226. Monti, D.; Ottolina, G.; Carrea, G.; Riva, S. Redox Reactions Catalyzed by Isolated Enzymes. Chem. Rev, 2011, 111, 4111-4140.
227. Salazar, O.; Cirino, P. C.; Arnold, F. H. Thermostabilization of a cytochrome P450 peroxygenase. ChemBioChem, 2003, 4, 891-893.
228. Eiben, S.; Bartelmas, H.; Urlacher, V. B. Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents. Appl. Microbiol. Biotech, 2007, 75, 1055-1061.
229. Kumar, S.; Zhao, Y.; Sun, L.; Negi, S. S.; Halpert, J. R.; Muralidhara, B. K. Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: Importance of a Leu264 to Phe substitution. Mol. Pharmacol, 2007, 72, 1191-1199.
230. Talakad, J. C.; Wilderman, P. R.; Davydov, D. R.; Kumar, S.; Halpert, J. R. Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: Insights into structural importance of residue 334. Arch. Biochem. Biophys, 2010, 494, 151-158.
231. Bloom, J. D.; Arnold, F. H. In the light of directed evolution: Pathways of adaptive protein evolution. Proc. Natl. Acad. Sci. USA, 2009, 106, 9995-10000.
232. Chefson, A.; Auclair, K. CYP3A4 activity in the presence of organic cosolvents, ionic liquids, or water-immiscible organic solvents. Chembiochem, 2007, 8, 1189-1197.
233. Zhao, J.; Tan, E.; Ferras, J.; Auclair, K. Activity of human P450 2D6 in biphasic solvent systems. Biotechnol. Bioeng, 2007, 98, 508-513.
234. Maurer, S. C.; Kuhnel, K.; Kaysser, L. A.; Eiben, S.; Schmid, R. D.; Urlacher, V. B. Catalytic hydroxylation in biphasic systems using CYP102A1 mutants. Adv. Synth. Catal, 2005, 347, 1090-1098.
235. Girhard, M.; Machida, K.; Itoh, M.; Schmid, R. D.; Arisawa, A.; Urlacher, V. B. Regioselective biooxidation of (+)-valencene by recombinant E. coli expressing CYP109B1 from Bacillus subtilis in a two-liquid-phase system. Microb. Cell Factories, 2009, 8.
236. Döhr, O.; Paine, M. J. I.; Friedberg, T.; Roberts, G. C. K.; Wolf, C. R. Engineering of a functional human NADH-dependent cytochrome P450 system. Proc. Natl. Acad. Sci. USA, 2001, 98, 81-86.
237. Elmore, C. L.; Porter, T. D. Modification of the nucleotide cofactorbinding site of cytochrome P-450 reductase to enhance turnover with NADH in vivo. J. Biol. Chem, 2002, 277, 48960-48964.
238. Neeli, R.; Roitel, O.; Scrutton, N. S.; Munro, A. W. Switching pyridine nucleotide specificity in P450BM3-Mechanistic analysis of the W1046H AND W1046A enzymes. J. Biol. Chem, 2005, 280, 17634-17644.
239. Landwehr, M.; Carbone, M.; Otey, C. R.; Li, Y. G.; Arnold, F. H. Diversification of catalytic function in a synthetic family of chimeric cytochrome P450s. Chem. Biol, 2007, 14, 269-278.
240. Chefson, A.; Zhao, J.; Auclair, K. Replacement of the natural cofactors by selected hydrogen peroxide donors or organic peroxides results in improved activity for CYP3A4 and CYP2D6. ChemBio-Chem, 2006, 7, 916-919.
241. Estabrook, R. W.; Shet, M. S.; Faulkner, K.; Fisher, C. W. The use of electrochemistry for the synthesis of 17-alpha-hydroxyprogesterone by a fusion protein containing P450C17. Endocrine Res, 1996, 22, 665-671.
242. Faulkner, K. M.; Shet, M. S.; Fisher, C. W.; Estabrook, R. W. Electrocatalytically driven omega-hydroxylation of fatty acids using cytochrome P450 4A1. Proc. Natl. Acad. Sci. USA, 1995, 92, 7705-7709.
243. Zhang, Z.; Nassar, A. E. F.; Lu, Z. Q.; Schenkman, J. B.; Rusling, J. F. Direct electron injection from electrodes to cytochrome P450(cam) in biomembrane-like films. J. Chem. Soc. Faraday Trans, 1997, 93, 1769-1774.
244. Mayhew, M. P.; Reipa, V.; Holden, M. J.; Vilker, V. L. Improving the cytochrome P450 enzyme system for electrode-driven biocatalysis of styrene epoxidation. Biotechnol. Prog, 2000, 16, 610-616.
245. Reipa, V.; Mayhew, M. P.; Vilker, V. L. A direct electrode-driven P450 cycle for biocatalysis. Proc. Natl. Acad. Sci. USA, 1997, 94, 13554-13558.
246. Schwaneberg, U.; Appel, D.; Schmitt, J.; Schmid, R. D. P450 in biotechnology: zinc driven omega-hydroxylation of pnitrophenoxydodecanoic acid using P450BM-3 F87A as a catalyst. J. Biotechnol, 2000, 84, 249-257.
247. Udit, A. K.; Arnold, F. H.; Gray, H. B. Cobaltocene-mediated catalytic monooxygenation using holo and heme domain cytochrome P450BM3. J. Inorg. Biochem, 2004, 98, 1547-1550.
248. Nazor, J.; Schwaneberg, U. Laboratory evolution of P450 BM-3 for mediated electron transfer. ChemBioChem, 2006, 7, 638-644.
249. Fasan, R.; Crook, N. C.; Peters, M. W.; Meinhold, P.; Buelter, T.; Landwehr, M.; Cirino, P. C.; Arnold, F. H. Improved Product-Per-Glucose Yields in P450-Dependent Propane Biotransformations Using Engineered Escherichia coli. Biotechnol. Bioeng, 2011, 108, 500-510.
250. Agematu, H.; Matsumoto, N.; Fujii, Y.; Kabumoto, H.; Doi, S.; Machida, K.; Ishikawa, J.; Arisawa, A. Hydroxylation of testosterone by bacterial cytochromes P450 using the Escherichia coli expression system. Biosci. Biotech. Biochem, 2006, 70, 307-311.